Navigation Links
Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its corporate partner, Pfizer (NYSE: PFE), has begun a Phase 1 clinical trial of an inhaled formulation of Rigel's small molecule syk kinase inhibitor, R343, for the treatment of allergic asthma. R343 is the third product candidate in Rigel's clinical portfolio.

Under the terms of the companies' 2005 collaboration agreement, Rigel will receive a $5 million milestone payment from Pfizer for the commencement of this study. Pfizer retains exclusive rights to R343 and is responsible for its clinical development.

"Developing an inhaled drug product that may address an important pathway in the allergic response causing asthmatic airway obstruction and tissue damage gives new hope to millions of asthma sufferers," stated Donald G. Payan, M.D., executive vice president and chief scientific officer of Rigel. "We are proud to have Pfizer lead the development of R343."

Syk Kinase Inhibition in Allergic Asthma

Allergic asthma is a chronic inflammatory disorder of the airways resulting in airway obstruction. In some patients, allergens, such as pollen, trigger the production of immunoglobulin E (IgE) antibodies, which then bind to mast cells and transmit intracellular signals causing the allergic response. In May 2006, Pfizer selected R343 for advanced preclinical development aimed at inhibiting IgE receptor signaling in respiratory tract
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , ... SRNE ;  Sorrento), an oncology company ... and Conkwest, Inc., a privately-held immuno-oncology company developing ... (NK) cell-line based therapy, announced today that the ... jointly develop next generation CAR-TNK™ (pronounced as "Car-Tank") ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ) ... Market Monitor: North American Dermatology Diagnostic Devices Market" ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic surgeries ... resulted in fueling the overall demand of the ... these dermatology devices is to assist in identifying ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... March 31 We may introduce the first,"A"- Implant novelty from Austria: ... - two-part system, - extraordinary stability, ... of most reliable Zirconium oxide, - Manufactured for your ... After 4 years of research and technical development, ...
... in new super pill ORLANDO, Fla. and DENVER, ... Board: CONX) announced today that its AspirinWorks Test ... Study (TIPS) to help determine patients, response to ... the effect of combinations of aspirin, statin and ...
Cached Medicine Technology:Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09 2Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09 3
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey ... decade. They’ve treated over 40,000 patients while carrying out ... alternative to the Paramus area. , For 2015, the ... staff of top-notch board certified physicians: Christine Milosis MD, Sandra ... new doctors will work tirelessly to carry out The ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... 20, 2014 Developers of FCPX ... a new plugin for Final Cut Pro X entitled ... Volume 5 allows users to create hand drawn text ... Christina Austin, CEO of Pixel Film Studios. “TranSlice Volume ... while maintaining an easy to use interface.” , TranSlice ...
(Date:12/20/2014)... The Twin Cities DI Day is recognized as the ... 250 financial professionals come together each year to hear ... motivated to protect their clients and to be inspired ... challenges of disability. , On September 23rd, 2014, financial ... attend The 13th Annual Twin Cities DI Day where ...
Breaking Medicine News(10 mins):Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3
... change and the story behind Antarctica’s icy ambience, is unraveled ... clue. ,An element pretty unheard of and extremely ... clue to the University of Florida geologists in estimating the ... have opened up. This has happened obviously millions of years ...
... is being prompted by the Drug Manufacturer, Wyeth to ... drugs to treat menopause.// The drugs are made as ... ,Following Wyeth's recommendation to the FDA, the agency ... these custom-made treatments, and have requested the agency not ...
... can explain why men and women experience pain differently ... certain pain-relief drugs, reveals a new study conducted by ... for Behavioral Neuroscience (CBN). ,Although the study ... that similar differences occur in humans as well. The ...
... report by the Food and Agriculture Organisation (FAO) of the ... species said that domestic and wild birds spread the bird ... since the start of the avian influenza crisis (the end ... the transmission of the virus in the natural setting. ...
... as a clean up drive legalisation of drugs is in ... drugs to addicts// to help clean up the Downtown Eastside ... Sullivan a donation by an anonymous donor of $500,000 to ... reason and goal behind this whole exercise would be to ...
... flu in Ethiopia has been dismissed by health officials, following ... for the presence of the H5N1 virus. ,Officials ... organized on Thursday that no outbreak of bird flu has ... in several parts of the country. ,All necessary ...
Cached Medicine News:Health News:Gender Difference In Pain Experience Explained By Brain Diversity 2
BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: